- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04357821
Combinatorial Therapy to Induce an HIV Remission
Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will perform a single arm study of twenty individuals with HIV infection on effective ART. All participants will receive a combination regimen administered during ART and then undergo an analytic treatment interruption. Our strategy has five stages
- IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4
- IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12
- MVA/HIV62B (MVA62B) boost at Week 20
- single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)
- ATI with single dose of VRC07 and 10-1074 at Week 34
Follow-up off ART will occur through at least Week 46 (expected) and on or off ART (depending on outcome) through Week 86.
Should this approach work, viral load would be expected to rebound in all individuals a few weeks after the bNAb levels decrease to sub-therapeutic levels. This acute rebound would be followed by a new lower viral load set-point and perhaps a long-term remission.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Zuckerberg San Francisco General Hospital, University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria
- Willing and able to provide written informed consent.
- Age ≤67 years at the time of enrollment for those who started treatment during early infection and <65 years for those who started treatment during chronic infection.
- Documented HIV-1 infection.
- On continuous antiretroviral therapy for at least 12 months without any interruptions of greater than 14 consecutive days within the last 1 year, and on a stable regimen that does not include an non-nucleoside reverse transcriptase inhibitor (NNRTI) for at least 4 weeks, without plans to modify ART during the study period.
- Screening plasma HIV RNA levels below the level of quantification on all available determinations in past 24 months.
- Screening CD4+ T-cell count ≥ 500 cells/mm3.
Key Exclusion Criteria
- Subjects receiving a non-nucleoside reverse transcriptase inhibitor
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- High-level resistance to both 10-1074 and VRC-07 as defined using the PhenoSense Neutralizing Antibody Assay (Monogram Biosciences).
- Any history of an HIV-associated malignancy, including Kaposi's sarcoma and any type of lymphoma, or virus-associated cancers.
- Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months.
- CD4+ T cell nadir <350 cells/mm3 during the chronic phase of infection (beginning 6 months following the estimated infection date and confirmed on repeat testing).
- Active hepatitis B (HBV) infection defined as positive HBV surface antigen test.
9. Active hepatitis C (HCV) infection. 10. Presence of significant abnormalities on electrocardiogram. 11. History of potential immune-mediated medical conditions. Individuals with isolated Raynaud's phenomenon or localized disease requiring topical therapy alone will not be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination intervention arm
All volunteers will receive the combination intervention outlined above.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who experience a new grade 3 or greater adverse event
Time Frame: Week 0 through 86
|
Week 0 through 86
|
|
Proportion of participants achieving post-treatment control.
Time Frame: Week 34 through 86
|
This will be defined as:
|
Week 34 through 86
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of any unsolicited adverse events for 28 days after administration of each study agent
Time Frame: Week 0 through 62
|
Week 0 through 62
|
|
Occurrence of any serious adverse events, medically attended adverse event, and potentially immune-mediated medical condition from the time of administration of the first study injection through 12 months after administration of the final study injection
Time Frame: Week 0 through 86
|
Week 0 through 86
|
|
Occurrence of two consecutive measurements HIV RNA >200 copies/mL using conventional assays
Time Frame: Week 34 to 86
|
Week 34 to 86
|
|
Resumptions of antiretroviral therapy after treatment interruption and the events that trigger them
Time Frame: Week 34 to 86
|
Week 34 to 86
|
|
Frequency of confirmed declines (two consecutive measurements) in CD4+ T cell counts (> 50%)
Time Frame: Week 34 to 86
|
Week 34 to 86
|
|
Frequency of confirmed declines (two consecutive measurements) to below 350 cells/mm3
Time Frame: Week 34 to 86
|
Week 34 to 86
|
|
Proportion experiencing any clinically defined episode of acute retroviral syndrome
Time Frame: Week 34 to 86
|
Week 34 to 86
|
|
Magnitude of T cell responses
Time Frame: Week 14
|
Week 14
|
|
Breadth of T cell responses
Time Frame: Week 14
|
The proportion of participants with at least one additional epitope response at week 14 (2 weeks after last vaccination) compared to their baseline response
|
Week 14
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 18-26957
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Combination Intervention
-
Northwestern UniversityNational Institute of Mental Health (NIMH)Not yet recruiting
-
Washington University School of MedicineNational Cancer Institute (NCI); Uganda Cancer Institute; Reach the Youth UgandaWithdrawn
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Johns Hopkins Bloomberg School of Public HealthMuhimbili University of Health and Allied SciencesCompleted
-
Pennington Biomedical Research CenterTerminatedCognitive ImpairmentUnited States
-
University of ThessalyGreek Multiple Sclerosis Society; European Committee for Treatment and Research...Active, not recruiting
-
M. MediciZonMw: The Netherlands Organisation for Health Research and Development; ACE...RecruitingAutoimmune HypothyroidismNetherlands
-
Columbia UniversityUnited States Agency for International Development (USAID)Completed
-
Sameera ShafiqNot yet recruitingPerinatal Depression | Perinatal AnxietyPakistan
-
David Grant U.S. Air Force Medical CenterCompletedTissue Perfusion | Pressure Distribution | Military Litters | Peak Pressure Index | Total Surface AreaUnited States